Cargando…

A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combinati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Junwen, Zhu, Xinyu, Chen, Pengfei, Du, Yanping, Lu, Yimin, Peng, Xiufan, Bao, Shuang, Wang, Junhua, Zhang, Xinting, Zhang, Tao, Pang, Clifford L.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190757/ https://www.ncbi.nlm.nih.gov/pubmed/32368355 http://dx.doi.org/10.1016/j.jare.2020.03.004

Ejemplares similares

A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer
por: Ou, Junwen, et al.
Publicado: (2020)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
por: Oriol, Albert, et al.
Publicado: (2021)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
por: Liu, Xiu, et al.
Publicado: (2023)

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison
por: Usmani, Saad Z., et al.
Publicado: (2017)

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
por: Ma, Helen, et al.
Publicado: (2020)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
por: Ying, Zhitao, et al.
Publicado: (2020)

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022)

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
por: Zagar, Timothy M., et al.
Publicado: (2014)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors
por: Lanciano, Rachelle, et al.
Publicado: (2012)

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
por: Roviello, Giandomenico, et al.
Publicado: (2019)

A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature
por: Ge, Ting-Ting, et al.
Publicado: (2023)

Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
por: Gui, Xinyu, et al.
Publicado: (2023)

Analysis of the activity and safety of weekly low‐dose bevacizumab‐based regimens in heavily pretreated patients with metastatic breast cancer
por: Zhai, Xiaoyu, et al.
Publicado: (2018)

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
por: Zhang, Pin, et al.
Publicado: (2016)

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
por: Smit, E. F., et al.
Publicado: (1998)

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
por: Yoo, Changhoon, et al.
Publicado: (2011)

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
por: Niu, Jiaxin, et al.
Publicado: (2015)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin’s lymphoma
por: Fukunaga, Akiko, et al.
Publicado: (2020)

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient
por: Lolli, Ginevra, et al.
Publicado: (2020)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

CAR‐T treatment: Determining the progression‐free survival gain in patients with heavily pretreated multiple myeloma
por: Messori, Andrea
Publicado: (2020)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study
por: Li, Zhenyu, et al.
Publicado: (2023)

The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis
por: He, Xiaoyan, et al.
Publicado: (2021)

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
por: Defferrari, Carlotta, et al.
Publicado: (2012)

An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
por: Gagliato, Debora de Melo, et al.
Publicado: (2016)

Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients
por: Amir, E, et al.
Publicado: (2009)

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2015)

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
por: Suzuki, Kenshi, et al.
Publicado: (2017)

Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
por: Cappuccio, Serena, et al.
Publicado: (2020)

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
por: SHERMAN, Shany, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4a1n6b3mvk2kt4aadh3jmjpgo